1Herbst RS,Bajorin DF,Bleiberg H,et al.Clinical Cancer Advances 2005:major research advances in cancer treatment,prevention,and screening--a report from the American Society of Clinical Oncology[J].J Clin Oncol,2006,24(1):190-205.
4Gill S,Sargent D.End points for adjuvant therapy trials:has the time come to accept disease-free survival as a surrogate end point for overall survival[J].Oncologist,2006,11 (6):624-629.
5Hartgrink HH,van de Velde C J,Putter H,et al.Extended lymph node dissection for gastric cancer:who may benefit? Final results of the randomized Dutch gastric cancer group trial[J].J Clin Oncol,2004,22(11):2069-2077.
6Sawyers C.Targeted cancer therapy[J].Nature,2004,432(7015):294-297.
7Gibbs JB.Mechanism-based target identification and drug discovery in cancer research[J].Science,2000,287(5460):1969-1973.
5[5]Kestle JR. Clinical trials. World J Surg, 1999, 23: 1205.
6[6]Mcleod RS. Issues in surgical randomized controlled trials. World J Surg. 1999, 23: 1210.
7[7]Eriksson S, Granstrom I. Randomized controlled trial of appendicectomy versus antibiotic therapy for acute appendicitis. Br J Surg, 1995, 82: 166.
8[8]Barie PS,Vogel SB, Dellinger EP, et al. A randomized double blind clinical trial comparing cefepime plus metronidazole with iripenem cilastatin in the treatment of complicated intra-abdominal infections: Cefepime Intra-abdominal Infection Study Group. Arch Surg, 1997, 132: 1294.
9[9]Brenneman FD, Wright JG, Kennedy ED, et al.Outcomes research in surgery. World J Surg, 1999,23: 1220.
10[10]Wright JG. Outcomes research: What to measure.World J Surg, 1999, 23: 1224.
